Hormonal status in patients with advanced prostatic cancer on the therapy with androgen blockade

Hormonal status in patients with advanced prostatic cancer on the therapy with androgen blockade

Background/Aim. Hormone suppression therapy is used in men with advanced prostate cancer improving chances of longer survival. The aim of this study was to investigate the influence of androgen blockades on testosterone and luteinizing hormone (LH) values in patients with locally advanced and me...

Full description

Bibliographic Details
Main Authors:	Vojinov Saša, Levakov Ivan, Jeremić Dimitrije, Živojinov Srđan, Marušić Goran
Format:	Article
Language:	English
Published:	Military Health Department, Ministry of Defance, Serbia 2011-01-01
Series:	Vojnosanitetski Pregled
Subjects:	prostatic neoplasms androgen antagonists luteinizinghormone testosterone prostate-specific antigen
Online Access:	http://www.doiserbia.nb.rs/img/doi/0042-8450/2011/0042-84501104321V.pdf

Similar Items

Immunohistochemical expression of androgen receptors in prostate carcinoma and benign prostatic hyperplasia
by: Trivunić-Dajko Sandra, et al.
Published: (2020-01-01)

Shifting the Paradigm of Testosterone Replacement Therapy in Prostate Cancer
by: Michael A. Bell, et al.
Published: (2018-05-01)

Adenocarcinoma of the prostate with small cell component and low levels of prostate specific antigen
by: Vojinov Saša, et al.
Published: (2020-01-01)

Factors associated with testosterone recovery after androgen deprivation therapy in patients with prostate cancer
by: Wook Nam, et al.
Published: (2018-01-01)

Androgens and prostate disease
by: Lori A Cooper, et al.
Published: (2014-04-01)

Recovery of hormone sensitivity after salvage brachytherapy for hormone refractory localized prostate cancer
by: Dan Smith, et al.
Published: (2010-06-01)

Reporting and ideal testosterone levels in men undergoing androgen deprivation for prostate cancer—time for a rethink?
by: Sonja Cabarkapa, et al.
Published: (2018-03-01)

Testosterone therapy in men with prostate cancer: literature review, clinical experience, and recommendations
by: Abraham Morgentaler, et al.
Published: (2015-04-01)

PROGNOSTIC VALUE OF THE BASELINE VALUES OF SERUM TESTOSTERONE AND FREE ANDROGEN INDEX IN PATIENTS WITH PROSTATE CANCER
by: M. E. Grigoryev, et al.
Published: (2014-08-01)

PROGNOSTIC VALUE OF THE BASELINE VALUES OF SERUM TESTOSTERONE AND FREE ANDROGEN INDEX IN PATIENTS WITH PROSTATE CANCER
by: M. E. Grigoryev, et al.
Published: (2014-08-01)

Association between the molecular markers, effect and time of response to the androgen-deprivation therapy in patients with prostate cancer
by: L. V. Spirina, et al.
Published: (2019-04-01)

Effect of androgen deprivation therapy on cardiovascular risk factors in prostate cancer
by: Mahnaz Roayaei, et al.
Published: (2013-01-01)

Androgen deprivation therapy is associated with decreased second primary lung cancer risk in the United States veterans with prostate cancer
by: Kyungsuk Jung, et al.
Published: (2018-08-01)

Expanding armamentarium in advanced prostate cancer management: are all novel antiandrogens the same?
by: Emre Yekedüz, et al.
Published: (2021-03-01)

Depression, Anxiety, and Patterns of Mental Health Care Among Men With Prostate Cancer Receiving Androgen Deprivation Therapy
by: Bohnert, A.S.B, et al.
Published: (2022)

Risk factors for bone loss with prostate cancer in Korean men not receiving androgen deprivation therapy
by: Sun-Ouck Kim, et al.
Published: (2009-04-01)

Questioning the evidence behind the Saturation Model for testosterone replacement therapy in prostate cancer
by: Jin Wook Kim
Published: (2020-05-01)

Physiological normal levels of androgen inhibit proliferation of prostate cancer cells in vitro
by: Weitao Song, et al.
Published: (2014-12-01)

Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide
by: Myungsun Shim, et al.
Published: (2019-07-01)

The castration level of testosterone and hormonal resistance of prostate cancer in androgen deprivation therapy
by: I. G. Rusakov, et al.
Published: (2020-12-01)

Could Testosterone Have a Therapeutic Role in Prostate Cancer?
by: Konstantinos Stamatiou
Published: (2013-03-01)

Chronic bacterial prostatitis associated with androgen deficiency
by: A Yu Zubkov, et al.
Published: (2020-06-01)

A gonadotropin-releasing hormone antagonist reduces serum adrenal androgen levels in prostate cancer patients
by: Yoshiyuki Miyazawa, et al.
Published: (2017-08-01)

Maximal androgen blockade for advanced prostate cancer
by: Rajiv Paul Mukha, et al.
Published: (2010-01-01)

Hormone naïve prostate cancer: predicting and maximizing response intervals
by: Judd W Moul
Published: (2015-01-01)

Titration of Androgen Signaling: How Basic Studies Have Informed Clinical Trials Using High-Dose Testosterone Therapy in Castrate-Resistant Prostate Cancer
by: Steven K. Nordeen, et al.
Published: (2021-08-01)

The Influence of Androgen Deprivation Therapy on Prostate Size and Voiding Symptoms in Prostate Cancer Patients in Korea
by: Hoon Choi, et al.
Published: (2016-12-01)

Economical impact of orchiectomy for advanced prostate cancer
by: Paula Adriano A. P. de, et al.
Published: (2003-01-01)

Testosterone inhibits the growth of prostate cancer xenografts in nude mice
by: Weitao Song, et al.
Published: (2017-09-01)

Androgen receptor and prostate cancer
by: Karen E. Livermore, et al.
Published: (2016-06-01)

Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients
by: Yue Wang, et al.
Published: (2017-01-01)

Role of maximum androgen blockade in advanced prostate cancer
by: Rajinikanth Ayyathurai, et al.
Published: (2009-01-01)

Enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: A retrospective Korean multicenter study in a real-world setting
by: Seung Il Jung, et al.
Published: (2020-01-01)

Use of docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in Korean patients: A retrospective study
by: Whi-An Kwon, et al.
Published: (2019-05-01)

Inefficient N2-Like Neutrophils Are Promoted by Androgens During Infection
by: María V. Scalerandi, et al.
Published: (2018-09-01)

Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level ≥ 50 ng/mL
by: Takeshi Kashiwabara, et al.
Published: (2018-05-01)

Contribution of allelic variability in prostate specific antigen (PSA) & androgen receptor (AR) genes to serum PSA levels in men with prostate cancer
by: Sushant V Chavan, et al.
Published: (2014-01-01)

The role of cannabinoids in prostate cancer: Basic science perspective and potential clinical applications
by: Juan A Ramos, et al.
Published: (2012-01-01)

EPIDEMIOLOGY OF AGE-RELATED ANDROGEN DEFICIENCY IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA
by: P I Chumakov, et al.
Published: (2018-12-01)

Combined tests of prostate specific antigen and testosterone will improve diagnosis and monitoring the progression of prostate cancer
by: Weitao Song, et al.
Published: (2015-01-01)